92:
reflecting excess mortality among cancer patients compared to the general population. In contrast to five-year absolute survival rates, five-year relative survival rates may also equal or even exceed 100% if cancer patients have the same or even higher survival rates than the general population. The pattern may occur if cancer patients can generally be cured, or patients diagnosed with cancer have greater socioeconomic wealth or access to medical care than the general population.
91:
survival rates describe the percentage of patients with a disease alive five years after the disease is diagnosed, divided by the percentage of the general population of corresponding sex and age alive after five years. Typically, cancer five-year relative survival rates are well below 100%,
134:
Five-year survival rates can be used to compare the effectiveness of treatments. Use of five-year survival statistics is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as
153:
242:
272:"Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis"
149:
To compare treatments independently from diagnostics, it may be better to consider survival from reaching a certain stage of the disease or its treatment.
226:
201:
107:
would increase chances of survival, compared to the general population. A more plausible explanation is that the pattern reflects a
246:
313:
Welch HG, Schwartz LM, Woloshin S (June 2000). "Are increasing 5-year survival rates evidence of success against cancer?".
443:
276:
146:
Improvements in rates are sometimes attributed to improvements in diagnosis rather than to improvements in prognosis.
120:
448:
116:
99:
The fact that relative survival rates above 100% were estimated for some groups of patients appears
350:"Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program"
84:
survival rates describe the percentage of patients alive five years after the disease is diagnosed.
60:
There are absolute and relative survival rates, but the latter are more useful and commonly used.
379:
420:
371:
330:
295:
222:
197:
69:
410:
361:
322:
285:
100:
140:
112:
104:
108:
54:
17:
437:
46:
383:
399:"Five-year survival rates and time trends of laryngeal cancer in the US population"
366:
349:
172:
57:
from earlier diagnosis can affect interpretation of the five-year survival rate.
136:
415:
398:
326:
290:
271:
173:"Cancer survival rate: A tool to understand your prognosis - MayoClinic.com"
50:
424:
375:
334:
299:
76:
statistics. Five-year absolute survival rates may sometimes also be cited.
53:
of a particular disease, normally calculated from the point of diagnosis.
348:
Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003).
73:
139:, and less useful in cases with a long life expectancy, such as
123:
population groups, who, in general, also have higher mortality.
156:(SEER) facilitates calculation of five-year survival rates.
221:. Boston: Jones and Bartlett Publishers. p. 30.
154:
Surveillance, Epidemiology, and End
Results database
103:on first view. It is unlikely that occurrence of
194:Epidemiology: with Student Consult Online Access
265:
263:
243:"ACS : How Is Colorectal Cancer Staged?"
8:
397:Cosetti M, Yu GP, Schantz SP (April 2008).
414:
365:
289:
270:Brenner H, Arndt V (January 20, 2005).
196:. Philadelphia: Saunders. p. 318.
164:
7:
119:tests tend to be used less often by
25:
403:Arch. Otolaryngol. Head Neck Surg
217:Varricchio, Claudette G. (2004).
72:rates are more commonly cited in
219:A cancer source book for nurses
152:Analysis performed against the
1:
367:10.1634/theoncologist.8-6-541
64:Relative and absolute rates
465:
416:10.1001/archotol.134.4.370
327:10.1001/jama.283.22.2975
291:10.1200/JCO.2005.11.148
43:five-year survival rate
18:Five year survival rate
125:
121:socially disadvantaged
192:Gordis, Leon (2008).
97:
27:Type of survival rate
444:Medical terminology
49:for estimating the
228:978-0-7637-3276-9
203:978-1-4160-4002-6
70:relative survival
16:(Redirected from
456:
429:
428:
418:
394:
388:
387:
369:
345:
339:
338:
310:
304:
303:
293:
267:
258:
257:
255:
254:
245:. Archived from
239:
233:
232:
214:
208:
207:
189:
183:
182:
180:
179:
169:
109:selection effect
101:counterintuitive
36:
21:
464:
463:
459:
458:
457:
455:
454:
453:
434:
433:
432:
396:
395:
391:
347:
346:
342:
312:
311:
307:
269:
268:
261:
252:
250:
241:
240:
236:
229:
216:
215:
211:
204:
191:
190:
186:
177:
175:
171:
170:
166:
162:
141:prostate cancer
132:
105:prostate cancer
66:
39:
34:
28:
23:
22:
15:
12:
11:
5:
462:
460:
452:
451:
446:
436:
435:
431:
430:
389:
340:
321:(22): 2975–8.
305:
259:
234:
227:
209:
202:
184:
163:
161:
158:
131:
128:
127:
126:
94:
93:
85:
65:
62:
55:Lead time bias
38:
37:
31:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
461:
450:
447:
445:
442:
441:
439:
426:
422:
417:
412:
408:
404:
400:
393:
390:
385:
381:
377:
373:
368:
363:
360:(6): 541–52.
359:
355:
351:
344:
341:
336:
332:
328:
324:
320:
316:
309:
306:
301:
297:
292:
287:
283:
279:
278:
273:
266:
264:
260:
249:on 2010-06-27
248:
244:
238:
235:
230:
224:
220:
213:
210:
205:
199:
195:
188:
185:
174:
168:
165:
159:
157:
155:
150:
147:
144:
142:
138:
129:
124:
122:
118:
114:
113:PSA screening
110:
106:
102:
96:
95:
90:
86:
83:
79:
78:
77:
75:
71:
63:
61:
58:
56:
52:
48:
47:survival rate
45:is a type of
44:
33:
32:
30:
19:
449:Epidemiology
409:(4): 370–9.
406:
402:
392:
357:
353:
343:
318:
314:
308:
284:(3): 441–7.
281:
277:J Clin Oncol
275:
251:. Retrieved
247:the original
237:
218:
212:
193:
187:
176:. Retrieved
167:
151:
148:
145:
133:
98:
88:
81:
67:
59:
42:
40:
29:
137:lung cancer
438:Categories
354:Oncologist
253:2009-10-11
178:2009-10-11
160:References
87:Five-year
80:Five-year
68:Five-year
117:screening
51:prognosis
425:18427002
384:35243360
376:14657533
335:10865276
300:15572727
89:relative
82:absolute
35: ()
423:
382:
374:
333:
298:
225:
200:
74:cancer
380:S2CID
115:, as
421:PMID
372:PMID
331:PMID
315:JAMA
296:PMID
223:ISBN
198:ISBN
130:Uses
41:The
411:doi
407:134
362:doi
323:doi
319:283
286:doi
111:of
440::
419:.
405:.
401:.
378:.
370:.
356:.
352:.
329:.
317:.
294:.
282:23
280:.
274:.
262:^
143:.
427:.
413::
386:.
364::
358:8
337:.
325::
302:.
288::
256:.
231:.
206:.
181:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.